Clinical Trials

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01670500 2026-05-05

Cisplatin vs. Doxorubicin/Cyclophosphamide in BrCa

118 enrolled 23 charts

Phase 1 Active not recruiting

Breast Neoplasms

NCT04521686 2026-04-22

Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations

200 enrolled

BreastCNSDermatologicGastrointestinalGenitourinaryHead & NeckSarcoma

Breast Neoplasms, Chondrosarcoma, Colonic Neoplasms, Glioblastoma, Glioma, Melanoma, Prostatic Neoplasms, Thyroid Neoplasms, Central Nervous System Neoplasms, Cholangiocarcinoma

NCT04595565 2026-04-22

SASCIA

Phase 3 Active not recruiting

1,332 enrolled

Phase 1 Active not recruiting

Triple Negative Breast Neoplasms

NCT04491942 2026-04-13

Testing the Addition of an Anti-cancer Drug, BAY 1895344, to the Usual Chemotherapy Treatment (Cisplatin, or Cisplatin and Gemcitabine) for Advanced Solid Tumors With Emphasis on Urothelial Cancer

74 enrolled

BreastGenitourinaryGynecologicOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Lung Neoplasms, Ovarian Neoplasms, Penile Neoplasms, Triple Negative Breast Neoplasms

NCT02595905 2026-04-08

Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

344 enrolled 11 charts

BreastCNS

Brain Neoplasms, Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02422498 2026-03-24

Homologous Recombination Repair Status as a Biomarker of Response in Locally Recurrent/Metastatic Triple Negative Breast Cancer Patients Treated With Concurrent Cisplatin and Radiation Therapy

49 enrolled 8 charts

Triple Negative Breast Neoplasms

NCT00003042 2026-02-20

Chemotherapy and Stem Cell Transplantation in Treating Patients With Stage IIIB Breast Cancer

41 enrolled 9 charts

Phase 2 Not yet recruiting

Breast Neoplasms, Inflammatory Breast Neoplasms

NCT07413601 2026-02-17

Phase 2 Clinical Study of Iparomlimab and Tuvonralimab (QL1706) in Combination With Platinum Chemotherapy Versus Platinum Chemotherapy in the Treatment of Second-/Third-line Triple Negative Breast Cancer (TNBC)

78 enrolled

Phase EARLY_PHASE1 Recruiting

Triple Negative Breast Neoplasms

NCT04265872 2026-02-12

Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

20 enrolled

Phase 1/2 Active not recruiting

Breast Neoplasms

NCT04711824 2025-12-23

SOLARA

Phase 1/2 Recruiting

41 enrolled

BreastCNS

Brain Neoplasms, Breast Neoplasms

NCT02393794 2025-10-06

Cisplatin Plus Romidepsin & Nivolumab in Locally Recurrent or Metastatic Triple Negative Breast Cancer (TNBC)

51 enrolled

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT01982448 2025-09-30

Cisplatin vs Paclitaxel for Triple Negative Breast Cancer

147 enrolled 15 charts

BreastGastrointestinalSarcoma

Triple Negative Breast Neoplasms

NCT02784795 2025-08-21

A Study of LY3039478 in Participants With Advanced or Metastatic Solid Tumors

Phase 1 Terminated

94 enrolled 28 charts

Breast Neoplasms, Colonic Neoplasms, Sarcoma, Cholangiocarcinoma

NCT05007106 2025-08-14

KEYVIBE-005

BreastGastrointestinalGenitourinaryGynecologicHead & Neck

613 enrolled

Parkinson Disease 4, Autosomal Dominant Lewy Body, Squamous Cell Carcinoma of Head and Neck, Urinary Bladder Neoplasms, Uterine Cervical Neoplasms, Esophageal Neoplasms, Gallbladder Neoplasms, Carcinoma, Hepatocellular, Ovarian Neoplasms, Stomach Neoplasms, Endometrial Neoplasms, Cholangiocarcinoma, Triple Negative Breast Neoplasms

NCT06900647 2025-04-02

BOCIS

Phase 1 Recruiting

20 enrolled

Breast Neoplasms

NCT03175666 2025-02-21

QUILT-3.049: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Combination Immunotherapy in Subjects With TNBC Who Have Progressed on or After Anthracycline-based Chemotherapy

Phase 1/2 Withdrawn

Triple Negative Breast Neoplasms

NCT02299999 2025-01-15

SAFIR02_Breast

1,460 enrolled

Phase 2 Not yet recruiting

Breast Neoplasms

NCT06746870 2024-12-24

A Phase II Clinical Study to Evaluate the Safety, Pharmacokinetic Profile, and Preliminary Efficacy of IMM2510 in Combination with Chemotherapy As First-line Treatment in Subjects with Non-small Cell Lung Cancer or Triple-negative Breast Cancer

148 enrolled

BreastThoracic

NSCLC

NCT02009449 2024-11-15

IVY

Phase 1 Completed

353 enrolled

BreastDermatologicGastrointestinalGenitourinaryGynecologicThoracic

Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Melanoma, Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Prostatic Neoplasms, Colorectal Neoplasms

NCT01074970 2024-09-19

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

135 enrolled 14 charts

BreastGastrointestinalThoracic

Breast Neoplasms

NCT03267316 2024-08-22

CANFOUR

Phase 1/2 Completed

167 enrolled

Carcinoma, Non-Small-Cell Lung, Neoplasms, Colorectal Neoplasms, Triple Negative Breast Neoplasms

NCT03387085 2024-08-09

QUILT-3.067: NANT Triple Negative Breast Cancer (TNBC) Vaccine: Molecularly Informed Integrated Immunotherapy in Subjects With TNBC Who Have Progressed on or After Standard-of-care Therapy.

Phase 1/2 Terminated

9 enrolled 18 charts

Triple Negative Breast Neoplasms

NCT06531447 2024-08-01

First-line Gemcitabine Plus Cisplatin in Locally Advanced (IIIC Stage) Breast Cancer Patients

200 enrolled

Phase 2 Not yet recruiting

Fibrosis Of Extraocular Muscles, Congenital, 3A, with or without Extraocular Involvement, Breast Neoplasms

NCT06510465 2024-07-19

NeoURANIA

143 enrolled

Breast Neoplasms

NCT04303988 2024-07-18

A Phase II Study of Triple-negative Breast Cancer Brain Metastases.

Phase 2 Recruiting

35 enrolled

Breast Neoplasms

NCT03982485 2024-04-30

APP

196 enrolled

Breast Neoplasms

NCT04537286 2024-02-26

First-line Nab-paclitaxel Plus Cisplatin Plus Carilizumab in mTNBC Patients

Phase 2 Unknown

90 enrolled

Phase 2/3 Not yet recruiting

Breast Neoplasms

NCT06268327 2024-02-20

Adding Adjuvant Cisplatin and Gemicitabine Versus Capecitabine in Triple-negative Breast Cancer Patients in Non pCR After Neoadjuvant Standard Chemotherapy

30 enrolled

Phase 2/3 Active not recruiting

Breast Neoplasms

NCT02641847 2024-01-25

TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature

503 enrolled

BreastGastrointestinalGenitourinaryGynecologicHead & NeckSarcomaThoracic

Breast Neoplasms, Triple Negative Breast Neoplasms

NCT02897375 2023-10-10

Palbociclib With Cisplatin or Carboplatin in Advanced Solid Tumors

Phase 1 Completed

71 enrolled

Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Head and Neck Neoplasms, Ovarian Neoplasms, Pancreatic Neoplasms, Sarcoma, Colorectal Neoplasms

NCT04265274 2023-10-06

Vinorelbine, Cisplatin, Disulfiram and Copper in CTC_EMT Positive Refractory Metastatic Breast Cancer.

Phase 2 Withdrawn

Breast Neoplasms

NCT05174832 2023-09-28

Induction of Cisplatin/Nab-paclitaxel/Pembrolizumab Followed by Olaparib/Pembrolizumab Maintenance in mTNBC Patients

Phase 2 Unknown

136 enrolled

Phase 2/3 Active not recruiting

Triple Negative Breast Neoplasms

NCT02221999 2023-08-29

SHPD002

250 enrolled

Carcinoma, Ductal, Breast, Inflammatory Breast Neoplasms

NCT03193853 2023-08-07

TAK-228 and TAK-117 Followed by Cisplatin and Nab Paclitaxel for Metastatic Triple Negative Breast Cancer

12 enrolled 11 charts